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Background: We sought to compare the baseline demographics, standard pathologic factors and long-term
clinical outcomes between ILC and infiltrating ductal carcinoma (IDC) using a large database.
Methods: Clinicopathologic features, overall survival (OS), and recurrence/metastasis-free survival (RFS) were
compared between 2,202 patients with IDC and 215 patients with ILC.
Results: ILC was significantly more likely to be associated with a favorable phenotype, but the incidence of
contralateral breast cancer was higher for ILC patients than for IDC patients (8.4% vs. 3.9%; P =0.001). The
frequencies of recurrence/metastasis (P= 0.980) and death (P= 0.064) were similar among patients with IDC and
patients with ILC after adjustment for tumor size and nodal status. The median follow-up was 42.8 months.
Conclusions: Chinese women with ILCs do not have better clinical outcomes than their counterparts with IDC.
Management decisions should be based on individual patient and tumor biologic characteristics, and not on
lobular histology.
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Lobular carcinoma is the next most common invasive
breast cancer histology after ductal carcinoma, accounting
for 8% to 14% of all breast cancers [1-4]. Invasive lobular
carcinomas (ILC) are believed to be more frequently mul-
ticentric and bilateral and may be distinguished from infil-
trating ductal carcinoma (IDC) histologically by its cell
type and pattern of invasion, as well as by its immunohis-
tochemical profile [5,6]. ILC is also reported to be more
difficult to palpate and to visualize with mammography
and has a distinctive pattern of metastatic spread [7,8].
Some epidemiologic studies have shown that for unknown* Correspondence: dgh_2011@yahoo.cn
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reproduction in any medium, provided the orreasons, the incidence of this type of breast cancer is
increasing, especially among postmenopausal women.
The morphologic features of ILC that are distinct from
those of IDC include small, round cells that are bland in
appearance and have scant cytoplasm [9]. Because ILC is
substantially less common than IDC, knowledge about
the clinical outcome of ILC has been based on analysis
including relatively small numbers of cases. ILC has
been reported to be associated with a poor, similar, or
better prognosis than IDC [10-12]. Only limited data
have been reported on the biologic features of lobular
carcinomas within the context of their clinical outcome.
However, some features such as age at diagnosis, tumor
size, lymph node status, histological grade, and stage of
disease are confirmed to be important prognostic factors
for survival in IDC patients [13-15].
We therefore undertook an extensive comparison of
ILC and IDC using a large database to provide a more. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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notypes and clinical behaviors. The present population-
based study elucidated the prognosis of women with ILC
and IDC with respect to recurrence/metastasis-free
survival (RFS) and overall survival (OS) among Chinese
women.Methods
Patients and follow-up
This study enrolled 2,417 patients, who were identified
histopathologically and treated at the Department of
Breast Surgery at Cancer Hospital/Institute, Fudan Uni-
versity (Shanghai, China) during the period from January
1, 1999 to October 1, 2010. These patients were all
female and divided into to an ILC group (215 cases) and
an IDC group (2,202 cases). Tumors were classified
histologically as ILC or IDC only according to the
criteria described by World Health Organization (WHO)
classification. Each patient was free of distant metastasis
at the time of the first diagnosis, and exhibited infiltra-
tive carcinoma. ILC was not further subtyped in these
databases, and patients with mixed ILC and IDC were
excluded. Also excluded patients with special histologic
types (pleomorphic, tubulo-lobular, or other variants
such as mucinous, medullary, and in situ cancer), and
patients with no histological confirmation of the diagno-
sis, cases identified from autopsy reports only, and
patients who did not undergo surgical treatment. Histo-
logic grade and lymphovascular invasion were not ana-
lyzed in the present study because in many cases this
information was not available, and E cadhaerin test was
used in part individuals of our cohort.
All patients were required to undergo a complete
physical examination, bilateral mammography, chest
radioscopy, ECG, ultrasonography of the breasts, axillary
fossa, cervical parts, abdomen and pelvis, and routine
blood and biochemical tests before surgery and accom-
panying adjuvant therapy, according to the standards
that were used during surgery. Some patients with early-
stage breast cancer were selected for SLNB. The SLN
was identified with blue dye (Methylthioninium Chloride
Injection, Jiangsu Jumpcan Pharmaceutical Co., Ltd.,
Shanghai, China) and/or radiocolloid (99 m-Technetium
sulfur colloid, CIS US Inc., Bedford, MA, USA). All of the
patients at risk of relapse received adjuvant chemotherapy
for four to six cycles followed by local radiotherapy (if
required) and/or hormonotherapy (if required) according
to the standard of therapy at the time of surgery. Follow-
up data were collected annually from medical records for
breast cancer recurrence, new primary cancers, and death.
Personal contact with the patient including routine corres-
pondence or telephone visits was used to follow the
patients. The follow-up examinations were performed atthe Cancer Hospital of Fudan University every 3 months
during the first 2 years, every 6 months during the next 2
years, and once a year thereafter.Methods for biological characteristics
The immunohistochemical status of each postoperative
paraffin-embedded tumor sample was defined through
immunohistochemical staining, including antibodies to
estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2/neu).
All of the primary monoclonal antibodies were purchased
from Dako, Hamburg, Germany. The detailed staining
procedures were performed strictly according to the man-
ufacturer’s instructions. Negative controls were obtained
by incubating parallel slides without primary antibodies.
Sections known to be stained positively in each run served
as positive controls. The percentage and intensity score of
stained tumor cells (ER, PR, HER2/neu) were determined
by at least two independent pathologists. The percentage
was interpreted as follows: 0, no staining observed; 1,
≤25% of cells with positive staining; 2, 25% to 50%; 3, 50%
to 75%; and 4, 75%. In terms of the intensity score, a score
of 0 referred to a negative result, 1 to a weakly positive
result, 2 to a moderately positive result and 3 to a strongly
positive result. Those two scores were combined and pro-
duced a final score. For all these markers except HER2/
neu staining, a score of 0 was defined as negative and 1 to
12 as positive, while strong membranous staining scores
of 9 to 12 (DAKO score 3+) were defined as positive.Statistical analysis
The association of clinicopathologic factors was evaluated
using Pearson’s Chi-square or Fisher’s exact tests. The
primary clinical outcomes for this study were recurrence/
metastasis-free survival (RFS) and overall survival (OS).
OS was defined as the time from the first diagnosis of
primary breast cancer to death from any cause, and
RFS was defined as the time from the same starting
point to local recurrence or metastasis. Survival time
was calculated from the date of surgery to these end-
points, censoring at the date of last contact and non-
breast primaries. The 5-year survival rate was calculated
using the Life Tables method. Survival curves were obtained
using the Kaplan-Meier method, and the log rank test was
used to determine the statistical significance in comparative
survival for a variety of patients and tumor characteristics.
All of the statistically significant variables observed in
univariate analysis were investigated by means of multi-
variate analysis using the Cox proportional hazards
model. All P values<0.05 were considered statistically
significant. All P values are two-sided. The SPSS 15.0 soft-
ware package (SPSS Inc) was used for statistical analysis.
Table 1 Proportion of invasive lobular and infiltrating ductal histologic types according to baseline characteristics
and treatment
Characteristics Invasive lobular Infiltrating ductal P value
(n=215) (n=2,202)
n % n %
Age (years)
≤50 112 52.1 1,138 51.7 0.483
>50 103 47.9 1,064 48.3
Bilateral involvement
Yes 18 8.4 85 3.9 0.001
No 165 76.7 2,086 94.7
Unknown 32 14.9 31 1.4
Tumor size
T≤ 2 103 47.9 623 28.3 <0.001
2<T≤ 5 96 44.7 1,277 58.0
T>5 15 7.0 170 7.7
Unknown 1 0.5 132 6.0
Nodal status
0 104 48.4 1,130 51.3 <0.001
1-3 53 24.7 559 25.4
4-10 26 12.1 347 15.8
>10 29 13.5 110 5.0
Unknown 3 1.4 56 2.5
TNM
I 61 28.4 433 19.7 <0.001
II 91 42.3 1,537 69.8
III 60 27.9 215 9.8
Unknown 3 1.4 17 0.8
ER status
Negative 74 34.4 1,167 53.0 <0.001
Positive 134 62.3 1,028 46.7
Unknown 7 3.3 7 0.3
PR status
Negative 78 36.3 1,100 50.0 <0.001
Positive 130 60.5 1,053 47.8
Unknown 7 3.3 49 2.2
HR status
Negative 54 25.1 785 35.6 0.004
Positive 154 71.6 1,395 63.4
Unknown 7 3.3 22 1.0
HER2/neu status
Negative 170 79.1 1,512 68.7 0.001
Positive 31 14.4 546 24.8
Unknown 14 6.5 144 6.5
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Table 1 Proportion of invasive lobular and infiltrating ductal histologic types according to baseline characteristics
and treatment (Continued)
Surgery
Mastectomy 202 94.0 2,122 96.4 0.079
BCS 13 6.0 80 3.6
Chemotherapy
Undo 25 11.6 230 10.4 <0.001
MTX included 25 11.6 857 38.9
Anthracycline included 128 59.5 980 44.5
Taxane included 32 14.9 30 1.4
Others 4 1.9 10 0.5
Unknown 1 0.5 95 4.3
Radiation therapy
Undo 152 70.7 1,718 78.0 0.001
Do 60 27.9 402 18.3
Unknown 3 1.4 82 3.7
Hormonotherapy
Undo 61 28.4 1,216 55.2 <0.001
Do 150 69.8 961 43.6
Unknown 4 1.9 25 1.1
BCS, breast-conserving surgery; HR, hormone receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
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Patient characteristics
Most patients with ILC presented with a palpable mass
(191 cases, 84.9%) or nipple discharge (4 cases, 1.9%);
13.2% (20 cases) of the patients only presented with
mammographic microcalcifications. We further reviewed
the manifestations on mammograms of every ILC patient
presenting with a palpable mass and found that 183 cases
(85.1%) were accompanied with abnormal radiological
changes, including 29 cases (13.5%) with malignant micro-
calcifications. When the IDC group was concerned, the
main primary manifestations at first diagnosis included
palpable mass (2,035 cases, 92.4%), microcalcifications
detected on mammograms (39 cases, 1.8%), nipple dis-
charge (72 cases, 3.3%), and breast pain, necrosis of the
nipple, or other rare symptoms (56 cases, 2.5%). The
same evaluations were also performed in those IDC
cases presenting with a palpable mass, and a similar
positive rate (92.7%, 1,886 cases) of mammographic fea-
tures was finally observed.
The ILC group comprised 215 cases that were between
the ages of 27 years and 85 years; the mean age was 52.5
years. The IDC group was composed of 2,202 cases aged
from 23 years to 90 years; the mean age was 51.8 years.
Table 1 (shown in supporting information) summarizes
the clinical and biologic tumor characteristics according
to histologic type. Compared with IDCs, ILCs were
much more likely to be bilateral (P= 0.001), and ILCs
were slightly smaller on average (47.9% smaller than 2 cm)than IDCs (28.3% smaller than 2 cm; P= 0.000). Further-
more, ILCs had a stronger association with early breast
cancer (TNM= I&II) (P <0.001) but presented a relatively
higher fraction of disease involving ≥4 axillary nodes
(P <0.001). More revealingly, the two groups seemed
not to be different in terms of the rate of lymph node
involvement (48.4% of patients with negative lymph
nodes among those with ILCs and 51.3% among those
with IDCs, respectively).
Despite the higher rate of bilateral involvement, ILCs
had more favorable biologic characteristics (Table 1).
The proportion of ER-positive tumors was 62.3% for
ILCs, but 46.7% for IDC (P < 0.001). PR was expressed
in 60.5% of ILCs and in 47.8% of IDCs (P <0.001).
Regarding HR (ER or PR) status, the ILC group also
had a relatively higher HR-positive rate (P = 0.004). As
for HER2/neu amplification status, ILCs were much
more likely to be negative (P = 0.001).
With regard to the adjuvant treatment methods, similar
proportions of ILC and IDC patients received adjuvant
chemotherapy. Likely due to the higher hormone receptor
content, adjuvant endocrine therapy was more frequently
given to patients with ILC (69.8%) than to those with IDC
(43.6%, P <0.001). However, the number of patients with
ILC who received adjuvant radiotherapy was slightly
higher (27.9% in ILC patients vs. 18.3% in IDC patients,
P=0.001).
The patterns of metastatic dissemination in ILCs and
IDCs are shown in Table 2. Lung or pleura, bone, distant
Table 2 Distant sites of first recurrence/metastasis in this
study
Sites ILC IDC P value
(n =183) (n = 2171)
Lungs/pleura 5 49 0.811
CNS 1 17 0.726
Ovary 0 3 NA
Gastrointestinal tract 0 1 NA
Nodes 3 53 0.478
Bone 10 107 0.892
Skin 4 33 0.566
Liver 3 37 0.798
Adrenal gland 1 1 0.170
CNS, central nervous system; IDC, invasive ductal carcinoma; ILC, invasive
lobular carcinoma; NA, not available.
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both ILCs and IDCs. As metastasis to unusual sites such
as the gastrointestinal tract and the ovaries did not
appear in ILCs, the difference in the incidence of these
metastatic diseases could not be determined. Informa-
tion on contralateral breast tumors was also availableFigure 1 Overall survival (A) and recurrence/metastasis-free survival (
recurrence/metastasis-free survival (D) in higher TNM (TNMII&III) stag
(positive vs. negative).among the subset of 2,354 patients in whom sites of
breast cancer distant from the primary site could be
assessed. Contralateral breast cancers in this group were
more frequent among those with ILC (9.8%) than among
those with IDC (3.9%; P= 0.001).
Univariate survival analysis
The median follow-up was 42.8 months (range, 5 to 135
months), 41.2 months for the ILC group vs. 42.9 months
for the IDC group. Contact with 63 patients was lost
during the follow-up period.
In our cohort, women diagnosed with ILC had a
similar likelihood of experiencing recurrence/metastasis
(P= 0.980) and death (P= 0.064) as those with IDC. Des-
pite having more favorable biologic characteristics, the
5-year OS and RFS were not better for ILC (83% and
82%) than for IDC (89% and 79%, Figure 1A and B).
When TNM stage was included in the analysis, ILCs
with higher TNM stage had a tendency to increase the
risk of death compared to those among IDCs (P= 0.057
for OS and P= 0.653 for RFS) (Figure 2A and B). ILC
was also one of the major predictors of worse overall
survival in the ER-negative group (Figure 3A, P= 0.007),B) according to histologic type; overall survival (C) and
e. *Adjusted for tumor size (≤2 vs.> 2 cm) and nodal status
Figure 2 (See legend on next page.)
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Figure 2 Overall survival (A) and recurrence/metastasis-free survival (B) according to ER negative; overall survival (C) and recurrence/
metastasis-free survival (D) according to PR negative; overall survival (E) and recurrence/metastasis-free survival (F) according to HR
negative; overall survival (G) and recurrence/metastasis-free survival (H) in HER2/neu negative. *Adjusted for tumor size (≤2 vs.>2 cm)
and lymph node status (positive vs. negative).
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group (Figure 3E, P= 0.021), and HER2/neu-negative
group (Figure 3G, P= 0.040).
Additionally, ILC women that received chemotherapy
had a higher rate of death (P= 0.023) compared to their
counterparts (Figure 3A).
Multivariate survival analysis
Multivariate survival analysis was performed to determine
whether ILC was an independent prognostic factor for
recurrence/metastasis and death. The factors included in
these analyses were histological type, age, tumor size,
nodal status, TNM stage, ER status, PR status, HR status,
HER2/neu status, and adjuvant treatment methods. From
among these variables, the factors that independently
associated with recurrence/metastasis, as well as with
survival in the general population, were as follows: nodal
status, TNM stage, ER status, PR status, and HR status
(Table 3).
In addition, to determine whether traditional prognos-
tic factors for IDC would be of value in patients with
ILC, a second set of multivariate analyses of RFS and OS
were performed in patients with ILC and IDC, respect-
ively (Table 3). For ILC, only nodal status and TNM
stage retained their independent prognostic value, while
hormone receptor status remained as a prognostic factor
in the IDC group, which is consistent with the findings
in the general population.
Once adjustments were made based on tumor size
and nodal status, histologic type did not emerge as
an important prognostic factor. Thus, the lack ofFigure 3 Overall survival (A) and recurrence/metastasis-free survival (
lymph node status (positive vs. negative).prognostic significance related to ILC vs. IDC in uni-
variate analyses is confirmed by the results of the
multivariate analyses.
Discussion
The present retrospective study demonstrated that ILC
has distinctive clinicopathologic characteristics com-
pared with IDC in a Chinese population. Largely in
agreement with other series, we revealed that ILC in
Chinese women was more likely to be smaller in size, of
a lower TNM stage, ER or PR positive, and HER2/neu
negative. Despite a substantially less aggressive biologic
phenotype, recurrence/metastasis and survival were very
similar between ILC and IDC patients.
Our database included the cases at an interval of 11
years, and the majority of these cases were treated be-
tween 1999 and 2005. The proportion of patients who
had breast mastectomy was very high (>95%) in this
period. Breast conservation has been increasingly used
during the past 5 years in our hospital, and up to 20% of
all patients underwent breast-conserving surgery (BCS)
in 2011. We found in our cohort that ILCs were treated
with BCS as often as IDCs, which was not consistent
with other published reports [16-18]. The recommenda-
tions against BCS for ILC were based on the consensus
that ILC was known to more often be multifocal, multi-
centric, and bilateral. The clinicians always preferred
mastectomy to BCS in the treatment of ILC. However,
there was recent evidence that BCS in ILC was not asso-
ciated with increased local relapse rates at 5 years when
compared with mastectomy [19,20]. In the currentB) in chemotherapy. *Adjusted for tumor size (≤2 vs.>2 cm) and
Table 3 Cox’s proportional hazards regression models for the general population, ILC and IDC groups
Variables RFS OS
RR (95% CI) P value RR (95% CI) P value
For general
Histological type 1.32 (0.82-2.12) 0.248 1.71 (0.91-3.21) 0.098
Age (years)≤ 50 1.23 (0.94-1.59) 0.131 1.43 (0.75-2.73) 0.284
Tumor size (cm) >2 1.47 (0.90-2.31) 0.124 1.71 (0.73-4.00) 0.215
Nodes positive 1.61 (1.37-1.88) <0.001 1.40 (1.08-1.81) 0.012
Higher TNM stage 1.56 (1.01-2.24) 0.016 1.78 (1.03-3.07) 0.039
ER positive 0.62 (0.43-0.91) 0.016 0.55 (0.31-1.00) 0.065
PR positive 0.59 (0.40-0.89) 0.011 0.51 (0.28-0.94) 0.031
HR positive 0.54 (0.32-0.91) 0.022 0.46 (0.21-1.02) 0.054
HER2/neu positive 1.21 (0.93-1.58) 0.157 1.24 (0.83-1.85) 0.304
Chemotherapy 0.57 (0.32-1.03) 0.060 0.57 (0.24-1.35) 0.200
Radiotherapy 0.54 (0.40-0.75) <0.001 1.21 (0.74-2.02) 0.414
Hormonotherapy 0.68 (0.51-0.90) 0.008 0.73 (0.47-1.13) 0.159
For ILC
Age (years)≤ 50 5.72 (0.83-39.32) 0.076 0.92 (0.81-1.04) 0.182
Tumor size (cm) >2 2.51 (0.61-10.41) 0.204 2.21 (0.97-5.01) 0.058
Nodes positive 2.87 (1.06-7.69) 0.038 5.55 (0.93-33.33) 0.060
Higher TNM stage 4.79 (2.79-11.85) 0.002 3.31 (2.15-9.45) 0.006
ER positive 1.04 (0.175-6.21) 0.964 1.98 (0.15-25.38) 0.600
PR positive 0.52 (0.10-2.58) 0.420 0.28 (0.02-3.24) 0.308
HR positive 0.66 (0.05-9.24) 0.760 0.39 (0.01-20.20) 0.643
HER2/neu positive 1.45 (0.41-5.18) 0.569 0.85 (0.21-3.42) 0.822
Chemotherapy 0.29 (0.02-4.73) 0.383 0.32 (0.12-1.05) 0.060
Radiotherapy 0.86 (0.27-2.78) 0.809 1.22 (0.26-5.72) 0.796
Hormonotherapy 1.38 (0.42-4.54) 0.595 0.90 (0.21-3.76) 0.889
For IDC
Age (years)≤ 50 1.21 (0.92-1.59) 0.186 1.55 (1.00-2.34) 0.049
Tumor size (cm) >2 1.39 (0.84-2.32) 0.201 2.34 (0.84-6.55) 0.105
Nodes positive 1.62 (1.37-1.91) <0.001 1.66 (1.27-2.17) <0.001
Higher TNM stage 1.52 (1.03-2.23) 0.056 1.93 (1.07-3.48) 0.029
ER positive 0.62 (0.42-0.93) 0.021 0.51 (0.27-0.97) 0.040
PR positive 0.60 (0.39-0.91) 0.016 0.47 (0.25-0.91) 0.025
HR positive 0.53 (0.31-0.92) 0.023 0.38 (0.16-0.88) 0.025
HER2/neu positive 1.19 (0.91-1.57) 0.206 1.26 (0.82-1.94) 0.292
Chemotherapy 0.60 (0.33-1.10) 0.099 0.82 (0.33-2.03) 0.662
Radiotherapy 0.51 (0.38-0.69) <0.001 0.47 (0.30-0.75) 0.002
Hormonotherapy 0.64 (0.47-0.86) 0.004 0.67 (0.42-1.08) 0.101
HR, hormone receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; OS, overall survival; RFS, relapse/metastasis free survival.
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did not identify any recurrence/metastasis or death
events at an average follow-up period of 39.0 months.
Although in practice, the histologic type appears to play
a role in the choice of surgical procedure selected, ILC
can indeed be treated with BCS (and radiotherapy) whenclear margins can be achieved. In the current study,
MRI test was used to evaluate every ILC patient receiving
BCS, and no one had received re-excision due to a positive
incised margin.
Concerning the pattern of metastatic spread, it seemed
that the ILC group of Chinese women was not different
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IDC were likely to affect the lungs or pleura, bone, and
liver. More frequent metastasis to unusual sites such as
the vulva and the gastrointestinal tract were previously
reported in ILC [21,22], but we could not address this
issue because of the limited cases analyzed in our data-
base. We found that the incidence of contralateral breast
cancer in women with ILC was nearly double that in
women with IDC; this finding could make a compelling
case for the use of tamoxifen to prevent contralateral
breast cancer in women with lobular primaries.
Most studies have demonstrated that ILC tumors
tended to be large [23-25], but 47.9% of ICLs were found
not to be in excess of 2 cm compared with only 28.3% of
IDCs in our data. We further revealed that a palpable
mass was observed in 202 cases (93.9%), and this was
the most frequent complaint, which might encourage
patients to participate in early screenings and obtain a
precise diagnosis when the tumor is smaller. Except for
the slightly smaller size of the ILCs, the rate of lymph
node involvement was comparable in each group; there-
fore, many more early-stage breast cancers were pre-
sented in the ILC group. To our knowledge, very few
previous studies had described these findings.
The current population-based study among Chinese
women also definitively validated the findings of some
published studies indicating that lobular carcinomas are
significantly more likely to be steroid receptor positive
than are IDCs [22]. We also evaluated the well-studied
growth factor receptors, HER2/neu. No more than 15%
of tumors classified as ILC over-expressed HER2/neu;
however, 24.8% of IDC patients displayed tumors that
overexpressed this receptor. Together these findings sug-
gest that ILC is biologically different from IDC, and has
more favorable biologic characteristics.
The RFS and OS curves showed an early advantage for
the ILC cohort, but after 4 years, an advantage emerged
for the IDC cohort. After adjustment for tumor size and
nodal status, there was no prognostic difference between
IDC and ILC in the current analysis, which indicated
that the more favorable prognostic factors of ILC did
not translate into a long-term survival advantage for
patients with ILC. We further clarified this important
finding through a multivariate analysis in different
groups. The favorable prognostic factors such as hor-
mone receptor status identified in the general population
and IDC group were not applicable in lobular carcin-
oma. In spite of the lack of survival differences between
ILC and IDC in most large datasets, the univariate ad-
verse prognostic effects of ILC phenotype had appeared
to be restricted to women with HR and HER2/neu-nega-
tive breast cancer, the majority of whom received adju-
vant chemotherapy. We therefore inferred ILC might be
associated with more aggressive biologic behavior thanIDC in some subgroups and induce a lack of responsive-
ness to chemotherapy treatment.
Two inherited limitations in this study should be
addressed. One potential weakness was the relatively
small sample of ILC, so the results in our analysis might
not comprehensively account for all the distinct biology
and exact prognosis of ILC. The other was that patho-
logic information for lymphovascular invasion and histo-
logic grade were excluded from the analysis, but these
variables could have an effect on survival. Therefore, fur-
ther studies with larger datasets and more complete
pathologic details will be necessary to validate our
findings.
Conclusions
Despite the fact that ILCs are epidemiologically and
phenotypically different from IDCs, these patients do
not have better clinical outcomes than do patients with
IDC. At present, management decisions should be based
on individual patient and tumor biologic characteristics,
and not on lobular histology.
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